

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MINGYUAN MEDICARE DEVELOPMENT COMPANY LIMITED

銘源醫療發展有限公司*

(Incorporated in Bermuda with limited liability)

(Stock code: 0233)

REVIEW REQUEST OF DECISION ON CANCELLATION OF LISTING

This announcement is made by Mingyuan Medicare Development Company Limited (the “Company”, together with its subsidiaries, the “Group”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities (the “Listing Rules”) on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement dated 15 July 2015 regarding the resumption conditions (the “Resumption Conditions”) imposed on the Company, the announcement dated 18 April 2019 regarding further resumption guidance (the “Further Resumption Guidance”) and the announcements dated 10 August 2018, 6 November 2018, 11 February 2019, 2 May 2019, 8 July 2019 and 2 August 2019 on the updates on trading suspension.

Terms defined in the aforementioned announcements shall have the same meaning herein unless otherwise defined or the context otherwise required.

The Company received a letter (the “Letter”) from the Stock Exchange on 16 August 2019 stating that as the trading in the Company’s securities has been suspended since 1 April 2015 and the Company failed to resume trading in its securities by 31 July 2019, the Listing Committee decided to cancel the Company’s listing under Rule 6.01A of the Listing Rules (the “Delisting Decision”). It is indicated in the Letter that the last day of listing of the Company’s shares would be on 30 August 2019 and the listing of its shares would be cancelled with effect from 9:00 a.m. on 2 September 2019 (the “Scheduled Date”).

** For identification purpose only*

After due consideration, the Company has on 27 August 2019 submitted a written request to the secretary of the Listing Review Committee of the Stock Exchange pursuant to Rule 2B.06(2) of the Listing Rules for a review of the Delisting Decision. On the same date, the Head of Listing of the Stock Exchange directed that in light of the Company's application for review, the cancellation of listing would not proceed on the Scheduled Date and the date of the review hearing would be provided in due course.

Should there be any material development, further announcement(s) will be made by the Company as and when appropriate.

CONTINUED SUSPENSION OF TRADING

Trading in the Shares on the Stock Exchange will remain suspended until further notice.

By Order of the Board
Mingyuan Medicare Development Company Limited
LAM Ping Cheung
Chairman

Hong Kong, 3 September 2019

As at the date of this announcement, the Board comprises (i) Mr. Lam Ping Cheung and Mr. Hui Yip Wing as executive Directors and (ii) Ms. Chan Mee Sze, Mr. Lam Suk Ping, Ms. Fan Stephanie Winnie and Mr. Cheung Chi Ming as independent non-executive Directors.